NRG Oncology, a cornerstone in clinical cancer research under the National Cancer Institute’s National Clinical Trials Network, has recently announced a strategic realignment in its leadership across several critical committees. This repositioning underscores the group’s commitment to advancing cancer research by leveraging the expertise of leading clinicians and investigators in oncology. The appointments feature distinguished figures whose innovative work spans translational science, surgical oncology, sarcoma research, investigator development, patient-centered outcomes, and medical oncology.
John Nakayama, MD, a luminary in gynecologic oncology and translational research, has been named Vice Chair of the NRG Ancillary Projects Committee, succeeding Dr. Bridget Koontz who ascended to Chair. Dr. Nakayama directs Translational Research within Allegheny Health Network’s Division of Gynecologic Oncology and serves as an associate professor at Drexel University College of Medicine. His pioneering efforts center on precision oncology, notably through the development and validation of circulating tumor DNA (ctDNA) biomarkers. His work involves rigorous analysis of homologous recombination deficiency and molecular residual disease, which holds significant sway in predicting patient responses to platinum-based chemotherapies. Dr. Nakayama’s leadership in integrating artificial intelligence and machine learning methodologies into gynecologic cancer research exemplifies the cutting edge of oncology. His models enhance predictions for ovarian cancer recurrence, anticipate chemotherapy toxicity profiles, and innovate with synthetic data applications — an intersection that promises personalized therapeutic adjustments.
In the realm of surgical oncology, Dr. Ibrahim Nassour, MD, MSCS, FACS, has advanced to Vice Chair of the NRG Surgical Oncology Committee. Dr. Nassour’s leadership at the University of Florida encompasses direction of robotic surgical programs and regional cancer therapies, facilitating translational research that improves gastric cancer patient navigation and care coordination. His involvement as a pivotal investigator in national clinical trials funded through the NCI’s network highlights his commitment to expanding evidence-based surgical interventions. Critical to his role is the facilitation of robotic surgery innovations and the integration of data-driven patient outcomes to elevate surgical oncology standards.
Turning to sarcoma, a historically challenging and heterogeneous group of malignancies, Dr. Scott Okuno, MD, assumes Vice Chair of the NRG Sarcoma Subcommittee. Dr. Okuno balances his responsibilities as Chief Medical Officer for the Sarcoma Alliance for Research through Collaboration with his academic leadership at Mayo Clinic. His research portfolio targets the development of novel, targeted therapies specially tailored to sarcoma subtypes, including leiomyosarcoma. Dr. Okuno’s involvement with multi-institutional clinical trials, such as ARST1321 investigating the role of pazopanib in combination with chemoradiation, addresses critical unmet needs in sarcoma treatment by exploring histology-specific biological pathways and therapeutic responses. This work marks a considerable step forward in precision oncology for sarcoma patients whose options have historically been limited.
Enhancing investigator development, Dr. Angeles Alvarez Secord, MD, MHSc, now leads as Chair of the NRG Investigator & Career Development Committee. Based at Duke University, Dr. Secord has fostered a broad consortium focused on the molecularly informed treatment of endometrial cancer, reflecting her dedication to translating molecular insights into practical therapeutic advances. Her leadership in mentoring emerging clinical investigators and her prior presidency of the Society of Gynecologic Oncology highlight her influential role in shaping the next generation of oncologic researchers. Dr. Secord’s work exemplifies the critical nexus of clinical trials, career development, and molecular oncology, driving forward new paradigms in cancer treatment and research mentorship.
Focusing on patient-reported outcomes and equitable health care, Dr. Samantha Tam, MD, MPH, FRCSC, was appointed Vice Chair of the NRG Patient-Centered Outcomes Research Committee. Leading research efforts at Henry Ford Health System, Dr. Tam has established comprehensive patient-reported outcome measures (PROMs) programs embedded within routine oncology practice. Her investigations into the implementation fidelity, equity implications, and clinical relevance of PROMs ensure that patient experiences and quality-of-life metrics become integral to cancer care protocols. At NRG, her role includes co-chairing PRO initiatives for head and neck cancer trials and spearheading cost-effectiveness analyses, bolstering the precision and patient orientation of research efforts.
In the domain of medical oncology, Dr. Christina Wu, MD, has been named Vice Chair of the NRG Medical Oncology Committee. Affiliated with Mayo Clinic Arizona, Dr. Wu’s translational research dissects the molecular and immunologic underpinnings of gastrointestinal cancers, with a particular emphasis on KRAS mutations and mismatch repair-deficient colorectal carcinomas. Her expertise encompasses early-phase clinical trials driven by biomarker stratification and innovative approaches utilizing artificial intelligence and liquid biopsy for risk assessment and recurrence prediction. Supported by prominent funding bodies, Dr. Wu’s work stands at the forefront of integrating cutting-edge molecular diagnostics into clinical protocols, with the goal of refining patient-specific treatment regimens and improving clinical outcomes.
NRG Oncology’s recent leadership transitions thus reflect a deliberate strategy to harness specialized expertise across diverse oncologic disciplines, fostering a collaborative environment where molecular insights, technological advancements, and patient-centered approaches coalesce. This dynamic leadership cadre is poised to influence the trajectory of clinical trial design, biomarker discovery, and translational research, ultimately accelerating the integration of personalized medicine into routine oncology care.
These appointments are not merely administrative changes; rather, they represent a profound investment in scientific innovation and rigorous clinical inquiry. The new leaders bring a spectrum of methodological sophistication, from molecular biology and bioinformatics to health services research and surgical innovation. This multifaceted expertise is critical in addressing the complex, multifactorial nature of cancer and its treatment, ensuring that NRG Oncology remains at the vanguard of research that directly improves patient survival, quality of life, and therapeutic precision.
NRG Oncology, continuing its legacy of integrating formerly independent research groups, maintains a robust infrastructure of over 1,300 research sites, predominantly in North America, enabling extensive clinical trial enrollment and high-quality data acquisition. These leadership enhancements will amplify the group’s capacity to execute landmark clinical trials that influence standard oncologic practice and policy.
The emphasis on novel biomarker development, AI-driven predictive modeling, and patient-reported outcome integration underscores a pivotal shift in cancer research—eschewing one-size-fits-all paradigms in favor of deeply personalized, data-rich strategies that are responsive to individual patient biology and experience. This leadership renewal within NRG Oncology embodies this transformative ethos, promising substantial advances in the fight against cancer.
For detailed information and updates on ongoing leadership and committee openings, stakeholders and prospective participants are encouraged to consult NRG Oncology’s official website which provides comprehensive listings and application timelines.
Subject of Research:
Cutting-edge leadership roles in translational oncology, surgical oncology, sarcoma research, investigator development, patient-centered outcomes, and molecular medical oncology within a leading cancer clinical trials network.
Article Title:
NRG Oncology Announces Strategic Leadership Realignment to Propel Cancer Research Innovation
News Publication Date:
Not explicitly stated (content references appointments effective 2026 and awards in 2025, indicating a future-dated publication)
Web References:
https://www.nrgoncology.org/Current-Openings
http://www.nrgoncology.org
Keywords:
NRG Oncology, cancer research, clinical trials, translational research, precision oncology, circulating tumor DNA, gynecologic oncology, surgical oncology, sarcoma, investigator development, patient-reported outcomes, medical oncology, artificial intelligence, biomarker-driven trials
Tags: artificial intelligence in oncology researchcirculating tumor DNA biomarkersclinical cancer research committeesgynecologic oncology translational researchhomologous recombination deficiency analysisinvestigator development in oncologymachine learning for cancer recurrence predictionmolecular residual disease in cancerNRG Oncology leadership expansionPatient-Centered Outcomes Researchprecision oncology in gynecologic cancerssarcoma clinical trials management
